Last update: March 17, 2019
Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.
A drug with hyperglycemic and antihypertensive action via peripheral vasodilatation.
Indicated orally (2 to 3 daily doses) in the treatment of unresponsive hyperglycemia by hyperinsulinism and intravenously in hypertensive crises.
Its use is authorized in the neonatal and infant period.
Since the last update we have not found any published data on its excretion in breast milk.
According to the limited pharmacokinetic data available (Pfizer 2017, Merck 2015), its high plasma protein binding could impede transfer to breastmilk, but its prolonged half-life, which would facilitate it, makes it prudent that, until more information about this drug is published in relation to breastfeeding, safer known alternatives may be preferable (Schaefer 2007 p685), especially during the neonatal period and in case of prematurity.
To minimize risks of exposure, it would be necessary to wait 5 days after the last dose to restart breastfeeding. Meanwhile, express and discard breastmilk regularly to maintain production.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM